180 related articles for article (PubMed ID: 31774464)
1. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.
Mayadev JS; Enserro D; Lin YG; Da Silva DM; Lankes HA; Aghajanian C; Ghamande S; Moore KN; Kennedy VA; Fracasso PM; Schilder RJ
JAMA Oncol; 2020 Jan; 6(1):92-99. PubMed ID: 31774464
[TBL] [Abstract][Full Text] [Related]
2. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).
Da Silva DM; Enserro DM; Mayadev JS; Skeate JG; Matsuo K; Pham HQ; Lankes HA; Moxley KM; Ghamande SA; Lin YG; Schilder RJ; Birrer MJ; Kast WM
Clin Cancer Res; 2020 Nov; 26(21):5621-5630. PubMed ID: 32816895
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of PD-1 inhibitor combined with concurrent chemoradiotherapy in locally advanced cervical cancer with pelvic and/or para-aortic lymph node metastases: a retrospective cohort study.
Liu C; Ran X; Wang Z; Zhang K
Chin Clin Oncol; 2023 Aug; 12(4):38. PubMed ID: 37699603
[TBL] [Abstract][Full Text] [Related]
4. Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.
Lheureux S; Butler MO; Clarke B; Cristea MC; Martin LP; Tonkin K; Fleming GF; Tinker AV; Hirte HW; Tsoref D; Mackay H; Dhani NC; Ghatage P; Weberpals J; Welch S; Pham NA; Motta V; Sotov V; Wang L; Karakasis K; Udagani S; Kamel-Reid S; Streicher HZ; Shaw P; Oza AM
JAMA Oncol; 2018 Jul; 4(7):e173776. PubMed ID: 29145543
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.
Mayadev J; Zamarin D; Deng W; Lankes H; O'Cearbhaill R; Aghajanian CA; Schilder R
Int J Gynecol Cancer; 2020 May; 30(5):701-704. PubMed ID: 31871115
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.
Shrivastava S; Mahantshetty U; Engineer R; Chopra S; Hawaldar R; Hande V; Kerkar RA; Maheshwari A; Shylasree TS; Ghosh J; Bajpai J; Gurram L; Gulia S; Gupta S;
JAMA Oncol; 2018 Apr; 4(4):506-513. PubMed ID: 29423520
[TBL] [Abstract][Full Text] [Related]
7. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
Mayadev J; Nunes AT; Li M; Marcovitz M; Lanasa MC; Monk BJ
Int J Gynecol Cancer; 2020 Jul; 30(7):1065-1070. PubMed ID: 32447296
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy after radiotherapy or concurrent chemoradiotherapy for pelvic lymph node-positive patients with locally advanced cervical cancer: a propensity score matching analysis.
Yuan Y; You J; Li X; Wang W
Int J Gynecol Cancer; 2022 Jan; 32(1):21-27. PubMed ID: 32474447
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
[TBL] [Abstract][Full Text] [Related]
11. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
[TBL] [Abstract][Full Text] [Related]
12. Outcome of international Federation of gynecology and obstetrics stage IIb cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study.
Guo L; Liu X; Wang L; Sun H; Huang K; Li X; Tang F; Li S; Yuan X; Wang C
Int J Gynecol Cancer; 2015 Jun; 25(5):910-8. PubMed ID: 25867278
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of alternating chemoradiotherapy by conformal radiotherapy combined with intracavitary brachytherapy for high-risk cervical cancer.
Hirata K; Kodaira T; Tomita N; Ohshima Y; Ito J; Tachibana H; Nakanishi T; Fuwa N
Jpn J Clin Oncol; 2014 Jun; 44(6):556-63. PubMed ID: 24755546
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial.
Huang H; Feng YL; Wan T; Zhang YN; Cao XP; Huang YW; Xiong Y; Huang X; Zheng M; Li YF; Li JD; Chen GD; Li H; Chen YL; Ma LG; Yang HY; Li L; Yao SZ; Ye WJ; Tu H; Huang QD; Liang LZ; Liu FY; Liu Q; Liu JH
JAMA Oncol; 2021 Mar; 7(3):361-369. PubMed ID: 33443541
[TBL] [Abstract][Full Text] [Related]
15. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
[TBL] [Abstract][Full Text] [Related]
16. Phase I Dose-Escalation Study of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in Stages IB2 and IIA2 Cervical Cancer.
Chou HH; Huang HJ; Lin H; Yang LY; Hsueh S; Liu FY; Liou YL; Liou JD; Chen MY; Chao A; Lin G; Chang TC; Lai CH
Am J Clin Oncol; 2017 Jun; 40(3):241-249. PubMed ID: 25350466
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer.
Garcia-Soto AE; McKenzie ND; Whicker ME; Pearson JM; Jimenez EA; Portelance L; Hu JJ; Lucci JA; Qureshi R; Kossenkov A; Schwartz L; Mills GB; Maity A; Lin LL; Simpkins F
Cancer; 2021 Jul; 127(13):2279-2293. PubMed ID: 33932031
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.
Klein O; Kee D; Nagrial A; Markman B; Underhill C; Michael M; Jackett L; Lum C; Behren A; Palmer J; Tebbutt NC; Carlino MS; Cebon J
JAMA Oncol; 2020 Sep; 6(9):1405-1409. PubMed ID: 32729929
[TBL] [Abstract][Full Text] [Related]
19. Concomitant Chemoradiotherapy With Image-guided Pulsed Dose Rate Brachytherapy as a Definitive Treatment Modality for Early-stage Cervical Cancer.
Refaat T; Castelain B; Small W; Elsaid A; Lotfy N; Lartigau E; Nickers P
Am J Clin Oncol; 2015 Jun; 38(3):289-93. PubMed ID: 23799285
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer.
Nogueira-Rodrigues A; Moralez G; Grazziotin R; Carmo CC; Small IA; Alves FV; Mamede M; Erlich F; Viegas C; Triginelli SA; Ferreira CG
Cancer; 2014 Apr; 120(8):1187-93. PubMed ID: 24615735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
